Targeting E. coli cells

JP2025525414A5Pending Publication Date: 2026-07-06SNIPR BIOME APS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SNIPR BIOME APS
Filing Date
2023-06-29
Publication Date
2026-07-06

AI Technical Summary

Technical Problem

Classical antibiotics are ineffective against multidrug-resistant B2 phylogenetic group E. coli strains such as ST131 and ST1193, leading to life-threatening infections in immunocompromised patients, and there is a need for alternative treatments that can selectively target and eliminate these strains without disrupting the microbiome.

Method used

A composition and method using transducing particles that attach to specific surface moieties (LPS, LamB, or Tsx) of B2 E. coli cells, delivering nucleases to cleave the genomic DNA and inhibit growth or kill the cells, thereby treating or preventing infections.

Benefits of technology

The approach effectively kills or inhibits the growth of multiple B2 E. coli strains, including ST131 and ST1193, reducing infection risk in immunocompromised patients, particularly those with UTIs or cancer, and preventing bacteremia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The technology described herein relates to methods and compositions for targeting E. coli cells, such as for treating or preventing infection by E. coli cells in a human or animal subject. In one embodiment, the method comprises administering to the subject a particle cocktail comprising a plurality of different transduction particles for E. coli cells. In one embodiment, the method comprises administering to the subject a plurality of transduction particles encoding nucleases for targeting the genome of B2 strain E. coli cells.
Need to check novelty before this filing date? Find Prior Art